Table of Contents
- Background of Kawasaki Syndrome
- Pathophysiology of Kawasaki Syndrome
- Etiology of Kawasaki Syndrome
- Epidemiology of Kawasaki Syndrome
- Presentation of Kawasaki Syndrome
- Differential Diagnosis of Kawasaki Syndrome
- Diagnosis and Workup of Kawasaki Syndrome
- Management and Treatment of Kawasaki Syndrome
- USMLE Questions
Background of Kawasaki Syndrome
Kawasaki syndrome or disease is a febrile vasculitic syndrome that comes as an acute illness and appears in early childhood. There are other names for the disease such as infantile periarteritis nodosa as well as mucocutaneous lymph node syndrome. The disorder was first described in 1967 in Japan by Dr. Tomisaku Kawasaki.
Initially, Kawasaki disease was thought to be self-limited and benign. However, later reports showed that about 2 % of patients died from the illness.
Pathophysiology of Kawasaki Syndrome
Even though, the obvious and prominent features of the disorder are mucocutaneous. The syndrome is best recognized as a generalized vasculitis involving small to medium arteries. It affects mainly the coronary vessels; however, it may also affect any other artery, vein or capillary.
In the early stages of the disorder, the vascular media as well as the endothelial cells become edematous; however, the internal elastic lamina will remain intact at this stage.
An influx of neutrophils will occur after 7–9 days from the onset of the fever, which will be followed by a proliferation of IgA-producing plasma cells and cytotoxic lymphocytes.
Multiple cytokines are secreted by the inflammatory cells including monocyte chemotactic and activating factor, vascular endothelial growth factor, and tumor necrosis factor. The inflammatory cells also secrete matrix metalloproteinases and interleukins targeting the endothelial cells, which will result in vascular damage.
The active inflammatory cells are replaced by monocytes and fibroblasts over the next few weeks to months. At this stage, fibrous connective tissue begins to develop within the wall of the vessel and intima thickens and proliferates, which will eventually result in narrowing of the vessel or the formation of a thrombus.
Etiology of Kawasaki Syndrome
According to most of the immunologic and epidemiological evidence, Kawasaki syndrome is most likely caused by an infection. However, the exact etiology remains unknown. Genetic predisposition as well as autoimmune reactions have also been suggested as possible etiologic factors for the disease.
Epidemiology of Kawasaki Syndrome
Approximately 3000 children are hospitalized in the United States every year because of Kawasaki syndrome.
Epidemics of the disease occur primarily during spring and late winter.
The syndrome appears to have higher incidence for Americans of Pacific Island and Asian descent, especially those of Japanese descent.
Japan was reported to have the highest incidence of the disorder, with a frequency of the diseases 20 times higher than in Western countries.
Other countries that show high incidence of the disease are Korea and Taiwan.
Presentation of Kawasaki Syndrome
The most common symptom that most children present with is a prolonged fever. Fever for at least 5 days is required in order to make the diagnosis.
Other nonspecific symptoms may precede the onset of the fever, which include:
- Joint pain
- Abdominal pain
- Decreased oral intake
The American Heart Association (AHA) established a diagnostic criteria, which includes fever for more than five days, plus 4 of these 5 main clinical features:
- Polymorphous rash: It is usually generalized; however, it could be limited to the lower extremities or the groin.
- Painless, nonexudative, bilateral bulbar conjunctival injection.
- Changes in the pharynx and oral cavity: Fissuring, erythema, strawberry tongue, crusting of the lips, and diffuse oropharyngeal mucosal injection.
- Acute cervical non purulent lymphadenopathy with diameter of lymph node more than 1.5 cm. This lymphadenopathy is usually unilateral.
- Peripheral extremities changes: edema or reddening of the soles and palms, which may be followed by Beau lines (transverse grooves across the toenails and fingernails) as well as membranous desquamation of the tips of toes and fingers.
Differential Diagnosis of Kawasaki Syndrome
It is important to diagnose Kawasaki diseases in early stages, because any delay in the diagnosis may result in devastating cardiac complications such as coronary artery aneurysms.
Numerous focal infections may mimic Kawasaki disease, including:
- Orbital cellulitis
- Retropharyngeal phlegmon
- Deep neck infection
- Preseptal cellulitis
- Cervical lymphadenitis
- Peritonsillar abscess
- Retropharyngeal cellulitis or abscess
Other differential diagnosis include:
- Toxic epidermal necrolysis
- Juvenile idiopathic arthritis
- Lyme disease
- Pediatric rocky mountain spotted fever
- Infantile polyarteritis nodosa
- Juvenile idiopathic arthritis
Diagnosis and Workup of Kawasaki Syndrome
The diagnosis of Kawasaki diseases depends mainly on the symptoms. In the initial phases of the condition, almost all patients suffer from increased levels of acute-phase reactants:
- C-reactive protein
- Erythrocyte sedimentation rate
Recently, two urine proteins are being used as biomarkers of Kawasaki syndrome, as they are diagnostically superior to CRP and ESR. These two urine proteins are filming C and merino A.
Management and Treatment of Kawasaki Syndrome
The main goal of management is to relieve the symptoms and prevent the formation of coronary artery disease. The principal step of treatment is the usage of full doses of intravenous immunoglobulin. Aspirin can also be used in the treatment of the condition.
Other medications that can be used in the management of the syndrome include:
- Cyclophosphamide or methotrexate: This is usually used in cases that are resistant to intravenous immunoglobulin treatment.
- Clopidogrel, dipyridamole and other anti platelet drugs: This is mainly used in patients with significant involvement of the coronary arteries and high risk for thrombus formation.
- Low-molecular-weight heparin, Warfarin, and other anticoagulants: Used in patients with high risk of thrombus formation, especially patients with large aneurysms.
- Infliximab can be used in patients suffering from refractory cases with coronary aneurysms.
- Corticosteroids are used in patients who do not respond to standard treatments and therapies.
1. A 32-year-old man presents to your office complaining of painful ulcerations on his feet and hands. He does not drink; however, he is a head smoker. By examination, you found that he is suffering from hypersensitivity to tobacco extract when injected intradermally. What is the most likely process responsible for the condition of this patient?
A. Segmental vasculitis of small and medium-sized arteries
b. Arteriolar wall concentric thickening
c. Renal arteries necrotizing inflammation
d. Increased permeability of endothelium
e. Granulomatous Eosinophil-rich inflammation
2. A 46-year-old man presents to your clinic complaining of weight loss, abdominal pain, numbness in his lower extremities, muscle weakness, and fever. A biopsy was taken from the sural nerve, which revealed fibrinoid necrosis and transmural inflammation of the small and medium arteries. He is seropositive for Hepatitis B and he has history of cigarette smoking as a teenager. The most likely diagnosis of this patient is:
a. Thromboangilitis obliterates
b. Systemic lupus erythematosis
C. Polyarteritis nodosa
d. Raynaud disease
e. Microscopic polyangitis